The Coalition for Epidemic Preparedness Innovations (CEPI) has launched an urgent, multi-pronged initiative to fast-track the development of three investigational vaccines targeting the Bundibugyo ebolavirus (BDBV). This move comes as the Democratic Republic of the Congo (DRC) and Uganda grapple with a concerning uptick in BDBV cases. With no currently licensed vaccines or therapeutics specifically for the Bundibugyo strain, the global health community is pivoting toward an accelerated research and development strategy to curb the spread of this lethal pathogen.
Following a rigorous global review process and extensive consultations with the World Health Organization (WHO), the Africa Centers for Disease Control and Prevention (Africa CDC), and other international health partners, CEPI has selected candidates from IAVI, Moderna, and the University of Oxford. The initiative represents a significant commitment of capital and technical resources aimed at bringing these candidates from the laboratory to the front lines of the epidemic.
The Core Challenge: Understanding the BDBV Threat
The Bundibugyo ebolavirus is a member of the Ebolavirus genus, responsible for periodic, devastating outbreaks in Central Africa. Historically, BDBV has been overshadowed by the Zaire ebolavirus, which has triggered the majority of known Ebola epidemics. Because BDBV outbreaks are relatively infrequent—with only two major documented occurrences prior to the current crisis—the development of medical countermeasures has lagged behind.
The current situation in the DRC and Uganda is particularly precarious. Public health officials emphasize that without a proactive vaccination strategy, the virus could continue to circulate in vulnerable, remote communities. "With the Bundibugyo virus spreading and no licensed vaccines available, every day counts in the race against this deadly disease," said Richard Hatchett, CEO of CEPI. "CEPI’s urgent funding and support for these three promising candidates aim to advance safe, effective vaccines to help control this epidemic."
Chronology of the Response
The race to develop a BDBV vaccine is a testament to the infrastructure built following the COVID-19 pandemic. The timeline of this intervention can be viewed through several critical phases:
- Detection and Consultation: Upon identifying the rising threat of the BDBV strain, CEPI mobilized an international expert advisory group. Working alongside the WHO and Africa CDC, the coalition mapped out the most viable technological pathways for rapid vaccine production.
- Candidate Selection: The selection of IAVI, Moderna, and the University of Oxford was based on the maturity of their underlying platforms and their proven history of success with other filoviruses.
- The Investment Phase (June 2026): CEPI formalized its financial commitment, providing targeted grants to each institution to accelerate manufacturing, preclinical testing, and the establishment of clinical trial protocols.
- Future Milestones: The coming months will focus on the generation of Master Virus Seed stocks and the transition to Good Manufacturing Practice (GMP) production, with the ultimate goal of launching Phase 1 human trials in late 2026.
Technical Approaches: Three Pillars of Defense
The strategy adopted by CEPI leverages three distinct, well-understood vaccine technologies, each offering unique advantages in terms of speed, scalability, and shelf-life.
1. IAVI’s rVSV Platform
The vaccine candidate from IAVI is rooted in recombinant vesicular stomatitis virus (rVSV) technology, originally developed at The University of Texas Medical Branch. This platform has already proven its mettle; it serves as the foundation for the only licensed Zaire ebolavirus vaccine and was successfully deployed during the 2025 Sudan virus outbreak in Uganda.
IAVI’s approach aims to provide protective immunity through a single dose. While the candidate has shown robust efficacy in non-human primate models, it remains untested in human populations. CEPI’s $3.2 million grant is earmarked for the critical work of establishing a Master Virus Seed stock and transferring complex manufacturing processes to a contract development and manufacturing organization (CDMO) capable of producing clinical-grade material.
2. Moderna’s mRNA Innovation
Moderna brings the speed of mRNA technology to the fight. Having utilized this platform to generate global defenses against COVID-19, the company is now adapting it for the Bundibugyo virus. CEPI has committed up to $50 million to this program, covering preclinical testing, Phase 1 trials, and concurrent manufacturing.
This "at-risk" manufacturing approach is a strategic gamble intended to save time. By producing doses while testing is still underway, the program aims to compress the timeline for moving into Phase 2 and Phase 3 trials. Moderna’s CEO, Stephane Bancel, emphasized the necessity of this approach: "We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
3. The University of Oxford’s ChAdOx1 Vector
The University of Oxford is utilizing its ChAdOx1 viral vector platform—the same technology that powered the AstraZeneca COVID-19 vaccine. This vector has demonstrated significant versatility, showing efficacy against various filoviruses, including Zaire ebolavirus, Sudan virus, and Marburg virus. CEPI’s $8.6 million investment supports the preclinical phase and the production of initial clinical batches, reinforcing the coalition’s commitment to proven, stable platforms.
Economic and Geopolitical Implications
The financial backing of these programs occurs against a complex economic backdrop for biotechnology firms. Moderna, for example, has seen year-over-year revenue fluctuations, reporting $0.4 billion in the first quarter of 2026. Despite a heavy investment in research and development—totaling $3.1 billion in 2025—the company faces the reality that specialized vaccines for rare diseases like BDBV are often commercially unviable for private firms to pursue alone.
CEPI’s intervention effectively de-risks these projects. By providing the necessary capital, the coalition allows companies like Moderna to continue refining their filovirus pipelines while simultaneously addressing an immediate public health emergency. This public-private partnership model is becoming the primary mechanism for tackling "neglected" tropical diseases that lack a traditional market incentive.
The Shifting Landscape of mRNA Research
The CEPI-Moderna partnership is particularly noteworthy given the cooling of support for mRNA technology in some Western nations. In August 2025, the U.S. government took the controversial step of terminating 22 federal contracts focused on mRNA vaccine development. In this context, CEPI’s commitment serves as a lifeline for the technology, ensuring that the progress made during the pandemic does not stagnate. By continuing to accumulate clinical data, these programs ensure that the world remains prepared for future outbreaks, regardless of the fluctuating political climate surrounding domestic research funding.
Official Responses and Strategic Coordination
The coordination of this effort is being managed at the highest levels of global health governance. CEPI is not acting in isolation; it is coordinating closely with Gavi, the Vaccine Alliance, the World Bank, and various development finance institutions. This "surge financing" strategy is designed to ensure that if these vaccine candidates successfully clear their clinical hurdles, there is immediate funding available for large-scale procurement and distribution.
The WHO, which played a pivotal role in vetting the candidates, has signaled that the IAVI rVSV candidate holds particular promise, given its similarity to existing, effective Ebola vaccines. However, by supporting three distinct platforms, CEPI is hedging against the possibility of failure. This portfolio approach is a core tenet of modern epidemic preparedness: never rely on a single solution when multiple viable pathways exist.
Conclusion: The Path Forward
The situation in the DRC and Uganda remains fluid. While the rapid development of these vaccines is a monumental scientific and logistical achievement, the success of these efforts will ultimately depend on the ability to conduct clinical trials in challenging, resource-limited environments.
CEPI continues to keep its doors open, maintaining an "open call for proposals" to evaluate additional candidates that might supplement the current efforts. As the research teams at IAVI, Moderna, and Oxford begin their work, the world watches with the hope that this investment will result in a tool that can finally bring the Bundibugyo ebolavirus epidemic to an end.
The history of viral outbreaks is defined by the gap between the arrival of a pathogen and the arrival of a vaccine. By investing in these three platforms, the global health community is actively working to close that gap, transforming the response to BDBV from a reactive tragedy into a managed, scientific success. The next phase of the crisis will be defined by how quickly these teams can move from the laboratory bench to the village clinic, a journey that is as much about logistics and community trust as it is about advanced biotechnology.
About the Author
